# ENCO-BRAF: HCP commentary report

> 36 verified statements (14 from clinicians verified by NPI or staff page) from 20 commentary sources · 5 findings · updated Oct 29, 2026

## Report

- Trial: A Phase II Study of the BRAF Inhibitor Encorafenib in Combination With the MEK Inhibitor Binimetinib in Patients With BRAFV600E-mutant Metastatic Non-small Cell Lung Cancer
- NCT ID: NCT04526782
- Registry: https://clinicaltrials.gov/study/NCT04526782
- Sponsor: Intergroupe Francophone de Cancerologie Thoracique
- Phase: Phase 2
- Status: Active, not recruiting
- Indications: Non-small cell lung cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-10-29
- Last checked: 2026-10-29
- Release hash: 60f424a19ecc0137e30d39024cb310dac57eccfa63d1854f42656d640e8cd0a3

## Counts

- HCP commentary sources screened: 35
- Sources cited by verified statements: 20
- Verified statements: 36
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 14
- Findings: 5
- People found in screened sources: 13
- Voices cited: 13
- Cited voices identity-verified: 11
- Organisational or shared accounts (not counted as people): 2

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

ENCO-BRAF asks how well encorafenib plus binimetinib treats metastatic BRAF V600E-mutant non-small cell lung cancer. An X poster welcomes the treatment option, while comparative positioning draws questions in an X thread. An X poster favors tolerability; progression-free survival comparisons draw scrutiny in X discussion. A YouTube interview speaker leaves sequencing and biomarker selection unresolved. The sources reviewed for this edition place the trial’s main results at ESMO 2024.

## Open Medical Affairs question

How should Medical Affairs explain clinical positioning, low-fever tolerability and sequencing without turning indirect evidence into superiority, exploratory factors into treatment rules, or study access into routine availability?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. The PFS discrepancy complicates comparative positioning
- F2. Low fever is attractive, but does not remove consequential toxicity
- F3. Sequencing and biomarker selection remain conditional
- F4. Updated response durability drives enthusiasm without proving equivalence across lines
- F5. Option and standard language coexist with distinct research-access concerns

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 5 | 5 | 5 | 4 | recorded | 3 |
| F2 | 7 | 8 | 6 | 6 | none recorded | 4 |
| F3 | 5 | 2 | 2 | 2 | none recorded | 3 |
| F4 | 6 | 3 | 3 | 3 | none recorded | 2 |
| F5 | 13 | 12 | 10 | 7 | none recorded | 4 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 0 | 1 | 0 | 4 | 0 | 5 | 0 | 5 posts and articles | yes |
| F2 | 0 | 0 | 3 | 1 | 3 | 7 | 1 | 6 posts and articles | yes |
| F3 | 2 | 2 | 0 | 0 | 1 | 5 | 0 | 1 post or article, 1 podcast or video | yes |
| F4 | 3 | 0 | 1 | 0 | 2 | 6 | 1 | 2 posts and articles, 1 podcast or video | yes |
| F5 | 12 | 0 | 0 | 0 | 1 | 13 | 0 | 10 posts and articles | yes |

### Trial dimensions

- Primary endpoint: Objective response rate: F2 (2 shared claims), F4 (2 shared claims)
- Secondary endpoint: Duration Response Rate: F2 (1 shared claims), F4 (2 shared claims)
- Secondary endpoint: Progression-free Survival: F1 (2 shared claims), F2 (2 shared claims), F4 (3 shared claims)
- Secondary endpoint: Overall Survival: F2 (2 shared claims), F4 (3 shared claims)
- Secondary endpoint: Incidence, type and severity of adverse events: F1 (1 shared claims), F2 (2 shared claims)
- Population and setting: F4 (4 shared claims), F5 (1 shared claims)
- The comparison: F4 (4 shared claims)
- Safety and tolerability: F1 (1 shared claims), F2 (5 shared claims)
- Design and conduct: F2 (1 shared claims), F4 (1 shared claims), F5 (1 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F1. The PFS discrepancy complicates comparative positioning

An X thread asks what might explain differences in progression-free survival between studies of the combination.

Source: X thread, 2024-09-14.

### F3. Sequencing and biomarker selection remain conditional

A YouTube interview addresses questions about treatment order and the role of biomarkers in sequencing.

Source: YouTube video, 2026-10-28.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 5 | Titles free |
| Detailed analysis | 6 sections | Paid |
| Verified statements with short source quotes and links | 36 | Paid |
| Trial aspects mapped | 15 | Free |
| Sources with links | 20 | Counts free |
| Speaker attribution for cited voices | 13 | Paid |

## Trial aspects

15 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Objective response rate | discussed | 4 | 3 |
| Secondary endpoint: Duration Response Rate | discussed | 3 | 2 |
| Secondary endpoint: Progression-free Survival | discussed | 7 | 5 |
| Secondary endpoint: Overall Survival | discussed | 5 | 4 |
| Secondary endpoint: Incidence, type and severity of adverse events | discussed | 3 | 3 |
| Population and setting | discussed | 5 | 3 |
| The comparison | discussed | 4 | 2 |
| Safety and tolerability | discussed | 6 | 5 |
| Design and conduct | discussed | 3 | 3 |
| Comparative positioning versus dabrafenib plus trametinib and PHAROS | discussed | 6 | 6 |
| Sequencing, smoking status and TP53 | discussed | 3 | 1 |
| Research access, enrollment and hoped-for treatment access | discussed | 4 | 4 |
| Earlier encorafenib–binimetinib evidence in BRAF V600E NSCLC | discussed | 7 | 4 |
| Treatment-option and standard-of-care language | discussed | 6 | 5 |
| Practice experience and an individual response example | discussed | 3 | 1 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 32 | 18 |
| YouTube | 2 | 2 |
| Bluesky threads | 1 | 0 |

- Screened window: 2023-06-04 to 2026-10-28
- Cited window: 2023-06-04 to 2026-10-28
- Retrieved: 2026-10-29

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase II Study of the BRAF Inhibitor Encorafenib in Combination With the MEK Inhibitor Binimetinib in Patients With BRAFV600E-mutant Metastatic Non-small Cell Lung Cancer
- Registry: NCT04526782 (https://clinicaltrials.gov/study/NCT04526782)
- Study IDs: IFCT-1904
- Sponsor: Intergroupe Francophone de Cancerologie Thoracique
- Design: Phase 2 · interventional, non randomized, parallel, phase2
- Status: Active, not recruiting
- Enrollment: 119 (estimated)
- Start: 2021-01-19 (actual)
- Primary completion: 2025-07-16 (actual)
- Primary endpoint: Objective response rate (6 months)
- Intervention: Encorafenib 75 MG (drug)
- Intervention: Binimetinib 15 MG (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on first-line combination efficacy and the immaturity of progression-free survival and response-duration follow-up.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 9 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- Nineteen of 37 original sources contain passages that were not fully assessed; additional relevant views may therefore be missing.
- Discussion using other wording or leaving the trial unnamed may be absent, including treatment-decision commentary relevant to the same population.
- The sources do not establish the prevalence of these views among HCPs. Reposts and source counts should not be interpreted as independent endorsements.
- A full protocol and an exact-trial results publication were unavailable for this edition, limiting assessment of methods and reported outcomes against a complete study report.
- Exact regulatory product information was unavailable. Approval, standard-of-care and access descriptions are presented as dated, attributed statements rather than independently confirmed jurisdictional conclusions.
- Earlier combination studies, PHAROS, ENCO-BRAF results and practice anecdotes must remain separate; their figures do not form a pooled efficacy or safety estimate.
- The October 2026 post and interview give different previously treated survival values, 37.5 and 35 months, without explaining the difference.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-29: current edition

Last checked for new commentary 2026-10-29. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (36 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (11 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/enco-braf-nct04526782
- Agents: POST https://www.erudio.com/api/orders with {"report": "enco-braf-nct04526782", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=enco-braf-04526782

## Cite

Erudio Health. ENCO-BRAF (NCT04526782): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 29, 2026. https://www.erudio.com/reports/enco-braf-nct04526782

## Machine access

- JSON: https://www.erudio.com/reports/enco-braf-nct04526782.json
- Markdown: https://www.erudio.com/reports/enco-braf-nct04526782.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "enco-braf-04526782"}`